RxDoctor Payments Data

John Wang, MD

Internal Medicine · Fountain Valley, CANPI 1720048291

Payments from drug & device makers

$1,655in general payments, 2019–2025

Across 25 payments — averaging $66.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$1K
  • Novartis$54
  • Pfizer$48
  • AstraZeneca$46
  • Seagen Inc.$40
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$32
  • plus $138 from 8 others

What the payments were for

  • Travel & lodging$1,23274%
  • Food & beverage$41125%
  • Education$131%

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,655 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$56,543
Medicare patients
290
Services billed
720

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban68$69,181
OzempicSemaglutide38$56,774
FarxigaDapagliflozin Propanediol33$36,091
JardianceEmpagliflozin17$29,297
JanuviaSitagliptin Phosphate24$28,343
XareltoRivaroxaban21$16,379
MounjaroTirzepatide12$11,403
MyrbetriqMirabegron14$9,007
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$8,417
OxycontinOxycodone Hcl11$7,801
TradjentaLinagliptin12$7,795
Tresiba Flextouch U-200Insulin Degludec13$7,459
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$7,372
VascepaIcosapent Ethyl14$6,942
Novolog FlexpenInsulin Aspart28$6,490

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$48$69,18168 claims
Novo NordiskOzempic$20$56,77438 claims
AstraZenecaFarxiga, Breztri Aerosphere$46$44,50846 claims
MerckJanuvia$11$28,34324 claims
Johnson & JohnsonXarelto$15$16,37921 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Fountain Valley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →